FOUNDING TEAM

Vance Lemmon, Ph.D. 
Co-founder
‚Äč
Hassan Al-Ali, Ph.D. 
Co-founder

Dr. Lemmon’s research activities focus on the use of phenotypic screening to identify gene targets and compounds that can be developed into therapeutics for nervous system repair. He is an internationally recognized expert in high throughput microscopy and analytical approaches to explore enormous image-based data sets. Dr. Lemmon has extensive experience in assay development, and has used ontologies, semantic reasoning, and artificial intelligence to identify novel targets for neural regeneration.

 

Dr. Al-Ali is a biochemist with expertise in biological, chemical, and computational sciences. He is an expert in assay development, including biochemical and cell-based assays for screening applications. Dr. Al-Ali brings extensive knowledge in the application of informatics and machine learning to early-stage drug discovery, and currently leads several projects within the areas of CNS injury, kidney disease, and cancer. 

 

Santiago Vilar, Ph.D. 
Scientist

Dr. Vilar is a computational chemist with broad experience in protein structure-based modeling, molecular simulations, and cheminformatics applied to drug discovery, design, and development. His expertise also includes the generation of multi-target, phenotype, and drug-drug interaction models in systems biology, pharmacovigilance, and data science.